Carnitine Palmitoyltransferase (CPT)

Carnitine palmitoyltransferase (CPT) is the central rate-limiting enzyme system for mitochondrial fatty acid β-oxidation, capable of converting palmitoyl-CoA into palmitoylcarnitine[1][2]. CPT transports long-chain acyl-CoA into the mitochondrial matrix, where it undergoes a transesterification reaction with free carnitine to generate acylcarnitine—the sole form in which long-chain fatty acids can traverse the mitochondrial inner membrane. The complete carnitine cycle is cooperatively executed by CPT1 on the mitochondrial outer membrane, CPT2 on the inner face of the inner membrane, and carnitine-acylcarnitine translocase (CACT), which mediates the exchange of acylcarnitine and free carnitine across the inner membrane. The activity of CPT directly determines the efficiency of cellular fatty acid oxidation[3][4]. The CPT1 enzyme system comprises three major isoforms: CPT1A (liver isoform), CPT1B (muscle isoform), and CPT1C (brain isoform). These isoforms exhibit significant differences in tissue distribution, functional regulation, and physiological and pathological roles, collectively constituting a complex metabolic regulatory network. In metabolic diseases (such as non-alcoholic steatohepatitis and obesity), the downregulation of CPT1A expression impairs fatty acid oxidation, thereby triggering lipid accumulation; conversely, in various malignancies, CPT1A is frequently overexpressed, providing energy for tumor cell proliferation and mediating drug resistance, thus serving as a critical node in metabolic reprogramming[3][4]. CPT1A activity is primarily subject to physiological inhibition by malonyl-CoA; however, under pathological conditions, it is subject to transcriptional regulation by various signaling pathways, including JAK2/STAT3 and AMPK. Furthermore, recent studies have revealed that CPT1A possesses non-metabolic functions, such as the regulation of histone acetylation. Intervention strategies targeting CPT vary markedly depending on the specific disease context: in metabolic disorders, activating CPT1A is required to enhance fatty acid oxidation—a process that can be upregulated, for instance, by the traditional Chinese medicine compound *Qushi Huayu* formula; conversely, in anti-tumor research, inhibiting CPT1A may be necessary to disrupt the energy supply, with inhibitors such as DHP-B having already demonstrated promising anti-tumor efficacy[1][2]. The CPT system has emerged as a pivotal molecular link connecting lipid metabolism with cell fate, positioning itself at the nexus—and as a major research hotspot—across diverse fields including metabolism, signal transduction, epigenetics, immunology, tumor biology, and precision medicine[1][2][3][4].

共 30种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
(+)-trans-C75
(+)-C75

(+)-trans-C75((+)-C75)是脂肪酸合成酶抑制剂 C75(MS-M55858)的一种对映体,其增强电离辐射抗癌能力的效力低于消旋混合物或 (-) 对映体,同时可抑制 CPT1 并具有食欲抑制作用。

1234694-20-2
Inhibitor
(+)-trans-C75
(S)-(+)-Etomoxir

(S)-(+)-Etomoxir 是 Etomoxir (MS-P30403) 的 S 对映体,而 Etomoxir 作为肉碱棕榈酰转移酶 1a (CPT-1a) 抑制剂,可通过抑制 CPT-1a 抑制脂肪酸氧化,并抑制人、大鼠和豚鼠中棕榈酸酯的氧化。

828934-40-3
Inhibitor
98.21%
(S)-(+)-Etomoxir
2,6-Didehydropeperomin B

DHP-B 是一种可从植物 Peperomia dindygulensis 中分离得到的 Ecolignan 类化合物,也是一种共价、选择性 CPT1A 抑制剂(Kd 为 1.62 μM),其通过与 CPT1A 的半胱氨酸 96 (Cys96) 共价结合阻断 FAO、破坏线粒体中 CPT1A-VDAC1 的相互作用,并可诱导凋亡 (Apoptosis),具有抗结直肠癌 (CRC) 活性。

1186292-00-1
Inhibitor
2,6-Didehydropeperomin B
4-Hydroxyphenylglyoxylate
4-Hydroxyphenylglyoxylic acid; 4-HPGA

4-Hydroxyphenglyoxylate(4-Hydroxyphenglyoxylic Acid)是肉毒碱棕榈酰转移酶 I(CPT I)的抑制剂,可抑制脂肪酸氧化,并可用于研究肝线粒体 CPT I 的敏感性变化及分离肝细胞的脂肪酸氧化。

15573-67-8
Inhibitor
99.69%
4-Hydroxyphenylglyoxylate
CPT1A Human Pre-designed siRNA Set A

CPT1A Human Pre-designed siRNA Set A 包含针对 CPT1A(Human)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。

Inhibitor
CPT1A Human Pre-designed siRNA Set A
Cpt1a Mouse Pre-designed siRNA Set A

Cpt1a Mouse Pre-designed siRNA Set A 包含针对 Cpt1a(Mouse)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。

Inhibitor
Cpt1a Mouse Pre-designed siRNA Set A
Cpt1a Rat Pre-designed siRNA Set A

Cpt1a Rat Pre-designed siRNA Set A 包含针对 Cpt1a(Rat)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。

Inhibitor
Cpt1a Rat Pre-designed siRNA Set A
CPT1B Human Pre-designed siRNA Set A

CPT1B Human Pre-designed siRNA Set A 包含针对 CPT1B(Human)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。

Inhibitor
CPT1B Human Pre-designed siRNA Set A
CPT1C Human Pre-designed siRNA Set A

CPT1C Human Pre-designed siRNA Set A 包含针对 CPT1C(Human)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。

Inhibitor
CPT1C Human Pre-designed siRNA Set A
CPT2 Human Pre-designed siRNA Set A

CPT2 Human Pre-designed siRNA Set A 包含针对 CPT2(Human)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。

Inhibitor
CPT2 Human Pre-designed siRNA Set A
Cpt2 Mouse Pre-designed siRNA Set A

Cpt2 Mouse Pre-designed siRNA Set A 包含针对 Cpt2(Mouse)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。

Inhibitor
Cpt2 Mouse Pre-designed siRNA Set A
Cpt2 Rat Pre-designed siRNA Set A

Cpt2 Rat Pre-designed siRNA Set A 包含针对 Cpt2(Rat)基因不同区域设计的三对 siRNA,以及阴性对照、FAM 标记阴性对照和阳性对照。

Inhibitor
Cpt2 Rat Pre-designed siRNA Set A

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础